Table 2.

Incidence of Hip Fracture by Baseline Trimethylamine N-oxide (TMAO) level in Quartiles

	Women		Men		Overall
	Hip fractures per Number at Risk, n	Incidence Rate (95% CI)^a	Hip Fractures per Number at Risk, n	Incidence Rate (95% CI)^a	Hip Fractures per Number at Risk, n	Incidence Rate (95% CI)^a
Quartile 1^b	134/775	1.17 (0.92, 1.49)	39/480	0.61 (0.41, 0.89)	173/1255	1.04 (0.57, 1.92)
Quartile 2^c	126/775	1.12 (0.88, 1.39)	36/481	0.58 (0.37, 0.91)	162/1256	0.93 (0.75, 1.34)
Quartile 3^d	126/774	1.14 (0.87, 1.49)	40/480	0.70 (0.49, 1.01)	162/1253	0.96 (0.77, 1.20)
Quartile 4^e	129/775	1.25 (0.91, 1.73)	36/479	0.71 (0.06, 8.01)	169/1255	1.02 (0.83, 1.26)
Total	515/3099	1.17 (1.02, 1.33)	151/1920	0.65 (0.34, 1.23)	666/5019	0.99 (0.82, 1.18)

Incidence rate is the number of hip fractures per 100 person-years. Incidence rates of hip fracture, total and across quartiles of TMAO, were calculated with quasi-Poisson model with offset to accommodate time at risk, unadjusted for covariates.

Quartile 1 of serum TMAO: 0.01 to 3.10 µmol/L in women; 0.45 to 3.56 µmol/L in men; 0.01 to 3.25 µmol/L overall

Quartile 2 of serum TMAO: 3.11 to 4.62 µmol/L in women; 3.57 to 5.24 µmol/L in men; 3.25 to 4.83 µmol/L overall

Quartile 3 of serum TMAO: 4.63 to 7.54 µmol/L in women; 5.25 to 8.43 µmol/L in men; 4.84 to 7.90 µmol/L overall

Quartile 4 of serum TMAO: 7.55 to 160.09 µmol/L in women; 8.44 to 254.99 µmol/L in men; 7.91 to 254.99 µmol/L overall